Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Cheng-Pang Hsu"'
Autor:
Po‐Wei Chen, Mats O. Karlsson, Sebastian Ueckert, Ari Pritchard‐Bell, Cheng‐Pang Hsu, Sandeep Dutta, Malidi Ahamadi
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1988-2000 (2023)
Abstract Erenumab is a fully human anti‐canonical calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. The Migraine‐Specific Quality‐of‐Life Questionnaire (MSQ) is a 14‐item patient‐reported out
Externí odkaz:
https://doaj.org/article/9612d46c23f444d0b99f937a4df1a826
Autor:
Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter, Andreas Baumann
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Monoclonal antibodies (mAbs) deliver great benefits to patients with chronic and/or severe diseases thanks to their strong specificity to the therapeutic target. As a result of this specificity, non-human primates (NHP) are often the only preclinical
Externí odkaz:
https://doaj.org/article/0dd48640109d457fb44fab13cc929494
Autor:
Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert
Publikováno v:
EBioMedicine, Vol 47, Iss , Pp 89-97 (2019)
Background: Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and aft
Externí odkaz:
https://doaj.org/article/c636d98304cf434ca98de4705a2ed3ba
Autor:
David W. Dodick, Andrew M. Blumenfeld, Rashmi B. Halker Singh, Rachel Williams, Feng Zhang, Po‐Wei Chen, Cheng‐Pang Hsu, Cheng Peng, Josefin Snellman, Mahan Chehrenama, Jessica Ailani
Publikováno v:
Headache: The Journal of Head and Face Pain. 63:233-242
Treatment wearing-off has been reported for calcitonin gene-related peptide-pathway monoclonal antibodies, including erenumab, specifically in the last week of the monthly dosing cycle.We sought to determine the consistency of erenumab effect through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0858764539dc9fec993b367a5bae3c44
https://doi.org/10.1111/head.14403
https://doi.org/10.1111/head.14403
Autor:
Patricia M. LoRusso, Greg Friberg, John S. Hill, Susan Wong, Yuying C. Hwang, Gloria Juan, Lovely Goyal, Cheng-Pang Hsu, Manuel Valdivieso, David S. Hong, Razelle Kurzrock, Roy S. Herbst
Supplementary Table 1. Adverse events at least possibly related to conatumumab treatment* Supplementary Table 2. Noncompartmental conatumumab pharmacokinetic parameters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50bf791261658d4c1bcbc20d8021333
https://doi.org/10.1158/1078-0432.22442178.v1
https://doi.org/10.1158/1078-0432.22442178.v1
Autor:
Patricia M. LoRusso, Greg Friberg, John S. Hill, Susan Wong, Yuying C. Hwang, Gloria Juan, Lovely Goyal, Cheng-Pang Hsu, Manuel Valdivieso, David S. Hong, Razelle Kurzrock, Roy S. Herbst
Purpose: To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors.Expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4eb52e595598c8c3c71b05c2e194e7f
https://doi.org/10.1158/1078-0432.c.6518985
https://doi.org/10.1158/1078-0432.c.6518985
Autor:
Patricia M. LoRusso, Greg Friberg, John S. Hill, Susan Wong, Yuying C. Hwang, Gloria Juan, Lovely Goyal, Cheng-Pang Hsu, Manuel Valdivieso, David S. Hong, Razelle Kurzrock, Roy S. Herbst
Supplementary Methods and Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c944c34eeb94799ffa3969c77beb3b
https://doi.org/10.1158/1078-0432.22442181.v1
https://doi.org/10.1158/1078-0432.22442181.v1
Autor:
Patricia M. LoRusso, Greg Friberg, John S. Hill, Susan Wong, Yuying C. Hwang, Gloria Juan, Lovely Goyal, Cheng-Pang Hsu, Manuel Valdivieso, David S. Hong, Razelle Kurzrock, Roy S. Herbst
Supplementary Materials and Methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e252e246cee3a13433890e7816d1c4
https://doi.org/10.1158/1078-0432.22442184
https://doi.org/10.1158/1078-0432.22442184
Publikováno v:
Journal of clinical pharmacology. 62(9)
We evaluated the pharmacokinetics, pharmacodynamics, and safety of a single subcutaneous dose of romosozumab 210 mg, a monoclonal antibody against sclerostin, in an open-label, parallel-group study in participants with severe (stage 4) renal impairme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73ec7ea54e598cd29d243ea955badb11
https://pubmed.ncbi.nlm.nih.gov/35304747
https://pubmed.ncbi.nlm.nih.gov/35304747
Autor:
Edward Lee, Sandeep Dutta, Winnie Sohn, Cheng-Pang Hsu, Stephen Flach, Pegah Jafarinasabian, Siddique Abbasi, Hanze Zhang, Shauna Hutton, Ashit Trivedi
Publikováno v:
Clinical pharmacology in drug development. 11(3)
Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and inhibitor of P-glycoprotein (P-gp), which can result i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c09162fe5b855e8b0ee0986e3cbfc09
https://pubmed.ncbi.nlm.nih.gov/34634185
https://pubmed.ncbi.nlm.nih.gov/34634185